"Glucosylceramidase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glycosidase that hydrolyzes a glucosylceramide to yield free ceramide plus glucose. Deficiency of this enzyme leads to abnormally high concentrations of glucosylceramide in the brain in GAUCHER DISEASE. EC 3.2.1.45.
| Descriptor ID |
D005962
|
| MeSH Number(s) |
D08.811.277.450.420.412
|
| Concept/Terms |
Glucosylceramidase- Glucosylceramidase
- beta-Glucocerebrosidase
- beta Glucocerebrosidase
- Acid beta-Glucosidase
- Acid beta Glucosidase
- beta-Glucosidase, Acid
- Glucocerebroside beta-Glucosidase
- Glucocerebroside beta Glucosidase
- beta-Glucosidase, Glucocerebroside
- Glucosylceramide beta-Glucosidase
- Glucosylceramide beta Glucosidase
- beta-Glucosidase, Glucosylceramide
- Glucosylsphingosine Glucosyl Hydrolase
- Glucosyl Hydrolase, Glucosylsphingosine
- Hydrolase, Glucosylsphingosine Glucosyl
- Glucosyl Ceramidase
- Ceramidase, Glucosyl
- Glucocerebrosidase
|
Below are MeSH descriptors whose meaning is more general than "Glucosylceramidase".
Below are MeSH descriptors whose meaning is more specific than "Glucosylceramidase".
This graph shows the total number of publications written about "Glucosylceramidase" by people in this website by year, and whether "Glucosylceramidase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 1 | 0 | 1 |
| 2012 | 2 | 0 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 2 | 2 |
| 2022 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glucosylceramidase" by people in Profiles.
-
Reply to: Cognitive Effects of Deep Brain Stimulation in GBA-Related Parkinson's Disease. Ann Neurol. 2022 08; 92(2):345-346.
-
Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in GBA Mutation Carriers. Ann Neurol. 2022 03; 91(3):424-435.
-
A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson's Disease in Participants With Leucine-Rich Repeat Kinase 2 Mutation. Clin Pharmacol Ther. 2021 08; 110(2):508-518.
-
Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nat Genet. 2021 03; 53(3):294-303.
-
Gait asymmetry in glucocerebrosidase mutation carriers with Parkinson's disease. PLoS One. 2020; 15(1):e0226494.
-
Cerebral Imaging Markers of GBA and LRRK2 Related Parkinson's Disease and Their First-Degree Unaffected Relatives. Brain Topogr. 2018 11; 31(6):1029-1036.
-
Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. JAMA Neurol. 2016 Oct 01; 73(10):1217-1224.
-
GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. Mov Disord. 2016 Jan; 31(1):95-102.
-
GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology. 2012 Nov 06; 79(19):1944-50.
-
Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology. 2012 May 01; 78(18):1434-40.